Stock · ZBH · Healthcare
United States · Large Cap · listed since 2001 · Revenue 12 mo. $8.5B
Price as of 11/06/2026
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Original text from the data provider
Summary
54.0 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €1.3B (2025), it supports €14.7B. The remaining €2.9B of the market value assume it grows 2.5% a year for 10 years and not at all afterwards.
Required FCF growth per year
2.5%
no growth afterwards
Price to operating cash flow 11.7×, below its usual range.
Middle half of 20 quarters: 13.2× to 18.4×, median 15.8×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
7 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, FCF margin, Net debt, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 5.55% | 11.52% | Rank 18 |
| Return on capital (Greenblatt) | 28.72% | 32.55% | Rank 43 |
| EBIT margin | 16.55% | 18.31% | Rank 45 |
| FCF margin | 17.89% | 14.12% | Rank 65 |
| Gross margin | 61.62% | 60.99% | Rank 51 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 7.20% | 8.04% | Rank 46 |
| Earnings growth, 3 years per year | 47.75% | 5.44% | Rank 91 |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 2.73% | 3.66% | Rank 32 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.36% | 2.90% | Rank 56 |
| FCF yield | 7.53% | 3.63% | Rank 89 |
| EV/saleslower is better | 3.22 | 4.03 | Rank 59 |
| EV/EBITlower is better | 19.44 | 21.73 | Rank 54 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 9.69% | 8.66% | Rank 53 |
| Share price, 6 months | 28.74% | 24.27% | Rank 63 |
| Share price, 3 months | 14.49% | 15.42% | Rank 48 |
| Distance from 52-week high | −4.14% | −7.35% | Rank 64 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 4.43% | 0.30% | Rank 19 |
| Change in share countlower is better | −2.55% | 0.00% | Rank 86 |
| Dividend streak in years | 13 | 10 | Rank 69 |
| Price reaction to results, market-adjusted | 2.50% | 0.05% | Rank 68 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 54.99% | 48.40% | Rank 61 |
| Net debt/EBITDAlower is better | 3.12 | 1.11 | Rank 15 |
| Debt to equitylower is better | 0.59 | 0.48 | Rank 44 |
| Volatility, 1 yearlower is better | 32.95% | 31.42% | Rank 46 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 7.7 | 10.7% | 1.4 | 202M | 10.6 |
| 2017 | 7.8 | 10.2% | 1.4 | 204M | 9.6 |
| 2018 | 7.9 | 0.4% | 1.6 | 204M | 8.4 |
| 2019 | 8.0 | 14.3% | 1.2 | 207M | 7.6 |
| 2020 | 6.1 | 1.4% | 1.1 | 207M | 7.3 |
| 2021 | 6.8 | 12.6% | 1.3 | 210M | 6.7 |
| 2022 | 6.9 | 10.0% | 1.1 | 210M | 5.3 |
| 2023 | 7.4 | 17.3% | 1.2 | 210M | 5.4 |
| 2024 | 7.7 | 16.7% | 1.1 | 204M | 5.7 |
| 2025 | 8.2 | 16.6% | 1.5 | 199M | 6.9 |
3 of 7 StockScorer Score rules met · How the score is built
Zimmer Biomet Holdings Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Zimmer Biomet Holdings Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Zimmer Biomet Holdings Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 29.8 | 30.0 |
| P/B ratio | 1.7 | 4.8 |
| Return on equity (ROE) | 5.6% | 11.5% |
| Equity ratio | 55.0% | 48.4% |
| Debt-to-equity (D/E) | 0.59 | 0.48 |
| Dividend yield | 0.9% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| ZBH | Zimmer Biomet Holdings Incthis page | |
| STE | STERIS plc | Low4.5 |
| GKOS | Glaukos Corp | locked |
| PEN | Penumbra Inc | locked |
| DXCM | DexCom Inc | locked |
| PODD | Insulet Corporation | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.